Cite

HARVARD Citation

    Christensen, H. et al. (n.d.). DOP57 GLP-1 based therapies and risk of Inflammatory Bowel Disease: real world evidence from a nationwide cohort study. Journal of Crohn's and colitis. p. i128. [Online]. 
  
Back to record